Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
New drug ixekizumab shows promise for children with arthritis
This multicentre, open-label, phase 3 study evaluated ixekizumab in 101 children with enthesitis-related arthritis or juvenile psoriatic art…
A phase 3 study found ixekizumab helped many children with arthritis meet response criteria at week 16, with mostly mild side effects report…
Systematic review and meta-analysis supports adalimumab plus methotrexate for JIA-associated uveitis
Combination therapy reduces relapse risk in children with eye inflammation from arthritis
This systematic review and meta-analysis of RCTs evaluated adalimumab plus methotrexate in children with juvenile idiopathic arthritis-assoc…
Combining adalimumab with methotrexate lowers relapse risk and helps reduce steroid use in children with arthritis-related eye inflammation.
Sudden sensorineural hearing loss risk factors in ankylosing spondylitis patients on adalimumab plus methotrexate
Could long-term arthritis treatment raise your risk of sudden hearing loss?
This retrospective case-control analysis drew on 2,564 ankylosing spondylitis patients at Henan Provincial People's Hospital (2015-2024), co…
Patients with long-term ankylosing spondylitis taking adalimumab and methotrexate are more likely to experience sudden hearing loss than tho…
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…